Division of Thoracic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Division of Thoracic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Thorac Surg Clin. 2014 Aug;24(3):305-11. doi: 10.1016/j.thorsurg.2014.05.001.
Large-cell neuroendocrine carcinoma (LCNEC) of the lung is an uncommon aggressive neoplasm with a poor prognosis compared with non-small-cell lung carcinoma (NSCLC). Because of its rarity, the treatment recommendations are not based on clinical trials, but are extrapolated from the approach to patients with NSCLC and small-cell lung carcinoma and the established literature for LCNEC, which is primarily retrospective in nature. Further studies should clarify the histology-specific characteristic and optimal therapeutic approach to establish the entity of LCNEC.
肺大细胞神经内分泌癌(LCNEC)是一种罕见的侵袭性肿瘤,与非小细胞肺癌(NSCLC)相比,预后较差。由于其罕见性,治疗建议并非基于临床试验,而是从 NSCLC 和小细胞肺癌患者的治疗方法以及 LCNEC 的既定文献中推断得出,这些文献主要是回顾性的。进一步的研究应该阐明组织学特异性特征和最佳治疗方法,以确立 LCNEC 的实体。